Bispecific Antibody

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has several limitations that may be overcome instead through bispecific T-cell-engaging antibodies, according to a speaker.

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

In this video, Sham Mailankody, MBBS discusses the latest in the study and treatment of multiple myeloma.

SAN DIEGO — In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of bispecific antibodies for lymphoma presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A treatment regimen of loncastuximab tesirine combined with venetoclax may be safe and effective in a subset of patients with non-Hodgkin lymphoma, according to early research presented at ASH Annual Meeting and Exposition.

In this video, Naval Daver, MD, discusses a presentation on updates in immune and cellular therapy in acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.

Sikander Ailawadhi, MD, discusses what’s new in the multiple myeloma space.

In this video, Tycel Phillips, MD, discusses treatment options available to patients with DLBCL.